Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Aridis Pharmaceuticals stock
Learn how to easily invest in Aridis Pharmaceuticals stock.
Aridis Pharmaceuticals is a biotechnology business based in the US. Aridis Pharmaceuticals shares (ARDS) are listed on the NASDAQ and all prices are listed in US Dollars. Aridis Pharmaceuticals employs 34 staff and has a trailing 12-month revenue of around $2.9 million.
How to buy Aridis Pharmaceuticals stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ARDS. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Aridis Pharmaceuticals stock price (NASDAQ: ARDS)Use our graph to track the performance of ARDS stocks over time.
Aridis Pharmaceuticals shares at a glance
|Latest market close||$1.23|
|52-week range||$0.68 - $2.94|
|50-day moving average||$1.02|
|200-day moving average||$1.26|
|Wall St. target price||$10.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-3.26|
Buy Aridis Pharmaceuticals stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Aridis Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Aridis Pharmaceuticals price performance over time
|1 week (2023-01-20)||4.24%|
|1 month (2022-12-27)||25.74%|
|3 months (2022-10-27)||23.46%|
|6 months (2022-07-27)||-12.14%|
|1 year (2022-01-23)||N/A|
|2 years (2021-01-27)||-81.50%|
|3 years (2020-01-27)||6.79|
|5 years (2018-01-23)||N/A|
Aridis Pharmaceuticals financials
|Revenue TTM||$2.9 million|
|Gross profit TTM||$-35,401,000|
|Return on assets TTM||-101.84%|
|Return on equity TTM||0%|
|Market capitalisation||$32.5 million|
TTM: trailing 12 months
Aridis Pharmaceuticals share dividends
We're not expecting Aridis Pharmaceuticals to pay a dividend over the next 12 months.
Aridis Pharmaceuticals share price volatility
Over the last 12 months, Aridis Pharmaceuticals's shares have ranged in value from as little as $0.68 up to $2.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aridis Pharmaceuticals's is 1.2007. This would suggest that Aridis Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Aridis Pharmaceuticals overview
Aridis Pharmaceuticals, Inc. , a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P.
Aridis Pharmaceuticals in the news
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
Frequently asked questionsWhat percentage of Aridis Pharmaceuticals is owned by insiders or institutions?
Currently 40.262% of Aridis Pharmaceuticals shares are held by insiders and 10.238% by institutions. How many people work for Aridis Pharmaceuticals?
Latest data suggests 34 work at Aridis Pharmaceuticals. When does the fiscal year end for Aridis Pharmaceuticals?
Aridis Pharmaceuticals's fiscal year ends in December. Where is Aridis Pharmaceuticals based?
Aridis Pharmaceuticals's address is: 983 University Avenue, Los Gatos, CA, United States, 95032 What is Aridis Pharmaceuticals's ISIN number?
Aridis Pharmaceuticals's international securities identification number is: US0403341045 What is Aridis Pharmaceuticals's CUSIP number?
Aridis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 040334104
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert